Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 25 - Drugs for disorders of the nervous system
Patents for A61P 25 - Drugs for disorders of the nervous system (183,225)
05/2010
05/11/2010US7714170 Bis- and tris-dihydroxyaryl compounds and their methylenedioxy analogs; Alzheimer's disease; diabetes; A beta amyloidosis
05/11/2010US7714120 Humanized anti-IL-1 beta antibodies
05/11/2010US7714118 recombinant vectors encoding the FK-520 polyketide synthase and FK-520 modification enzymes can be used to produce the FK-520 polyketide; for immunosuppression or to stimulate nerve growth and regeneration
05/11/2010US7714108 Mammalian tumor susceptibility gene products and their uses
05/11/2010US7714105 Use of fragments of oxytocin for the preparation of a pharmaceutical composition in order to create eustasis
05/11/2010US7714013 Azole derivatives and fused bicyclic azole derivatives as therapeutic agents
05/11/2010US7714003 Imidazo[2,1-b ]-1,3,4-thiadiazole sulfonamides
05/11/2010US7713995 Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases
05/11/2010US7713992 adenosine receptor antagonists such as 2-(4-Methoxyphenyl)-9-benzylamino-10-cyano-s-triazolo[1,5-a]quinolin, used for treating respiratory system disorders, vision disorders, tumors, allergies or inflammatory disease, ischemia, hypoxia, arrhythmia or urogential disorders
05/11/2010US7713963 Acylated indanyl amines and their use as pharmaceuticals
05/11/2010US7713957 Pharmaceutical composition containing gabapentin or pregabalin and N-type calcium channel antagonist
05/11/2010US7713956 Dealkylated derivatives of pyrrolo[2,1-b]benzothiazepines with atypical antipsychotic activity
05/11/2010US7713949 Compositions and methods for enhancing paracellular permeability across epithelial and endothelial barriers
05/11/2010CA2598516C Benzisoxazole derivatives
05/11/2010CA2488868C Controlled release formulation of lamotrigine
05/11/2010CA2462110C Phenyl-piperazine derivatives as serotonin reuptake inhibitors
05/11/2010CA2422299C Triazole compounds useful as protein kinase inhibitors
05/11/2010CA2415532C Novel 4-phenyl substituted tetrahydroisoquinolines therapeutic use thereof
05/11/2010CA2412968C Substituted pyridines as selective cyclooxygenase-2 inhibitors
05/11/2010CA2410177C Thrombin receptor antagonists
05/11/2010CA2409674C Glutamic acid decarboxylase (gad) based delivery systems
05/11/2010CA2392570C 4-pyrimidinyl-n-acyl-l-phenylalanines
05/11/2010CA2378603C Benzofuran derivatives
05/11/2010CA2326401C Molecular regulatory circuits to achieve sustained activation of genes of interest by a single stress
05/06/2010WO2010050585A1 Vector for treating alzheimer's disease
05/06/2010WO2010050577A1 Cyclohexane derivative and pharmaceutical use thereof
05/06/2010WO2010050461A1 Novel amide derivative and use thereof as medicine
05/06/2010WO2010050456A1 Piperidine compound having di- or tri-arylmethyl structure
05/06/2010WO2010050436A1 Piperidine derivative, piperazine derivative and agent for treatment of disease involving central nervous system disorders
05/06/2010WO2010050435A1 Cyclohexylamine derivative containing phenyl group, and therapeutic agent for diseases accompanied by central nervous system disorders
05/06/2010WO2010050422A1 Agent for treatment of diabetes
05/06/2010WO2010049841A1 7-azaspiro [3.5] nonane-7-carboxamide compounds as modulators of fatty acid amide hydrolase
05/06/2010WO2010049635A1 Tropane urea derivatives, preparation thereof and therapeutic application thereof as modulators of the activity of 11betahsd1
05/06/2010WO2010049366A1 Tricyclic compounds as glutamate receptor modulators
05/06/2010WO2010049146A1 Substituted spiroamines
05/06/2010WO2010028651A3 Method of upregulating sorla for the treatment of alzheimer's disease
05/06/2010WO2010024911A8 Methods for increasing neurogenesis
05/06/2010WO2010017368A3 Methods and compositions for treating anxiety
05/06/2010WO2010017224A3 Methods of treating cognitive impairment
05/06/2010WO2010012964A3 Thiophene-2-carboxamide derivatives, preparation thereof and therapeutic use thereof
05/06/2010WO2010011836A3 Treating various disorders with 7,8-dihydroxyflavone and derivatives thereof
05/06/2010WO2010011811A4 3-(phenoxyphenylmethyl)pyrrolidine compounds
05/06/2010WO2010004221A3 Use of indole derivatives as nurr-1 activators for treating parkinson’s disease
05/06/2010WO2009143347A3 Varenicline tosylate, an intermediate in the preparation process of varenicline l-tartrate
05/06/2010WO2009106749A3 Derivatives of n-heterocyclic-imidazo[1,2-a]pyridine-2-carboxamides, preparation thereof and therapeutic application thereof
05/06/2010US20100113810 Treatment of neurodegenerative conditions
05/06/2010US20100113796 Indole derivatives as s1p1 receptor
05/06/2010US20100113742 Modified polypeptides stabilized in a desired conformation and methods for producing same
05/06/2010US20100113613 cyclohexane polyalcohol formulation for treatment of disorders of protein aggregation
05/06/2010US20100113605 Methods, compositions and uses thereof
05/06/2010US20100113599 Amphipathic carboxylates for the treatment of immune-related disorders
05/06/2010US20100113595 Treatment of neurodegenerative conditions
05/06/2010US20100113591 Methods and compositions for treating amyloid-related diseases
05/06/2010US20100113587 use of abscissic acid to treat various diseases, including neurodegenerative and neuromuscular diseases
05/06/2010US20100113579 Prodrugs of excitatory amino acids
05/06/2010US20100113570 Prevention and treatment of post-operative cognitive dysfunction
05/06/2010US20100113555 Modulators of ATP-Binding Cassette Transporters
05/06/2010US20100113549 Pyrrolidine compounds
05/06/2010US20100113546 Imidazol-4-one and Imidazole-4-thione Compounds
05/06/2010US20100113545 Glyt1 transporter inhibitors and uses thereof in treatment of neurological and neuropsychiatric disorders
05/06/2010US20100113541 Crystal forms of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol
05/06/2010US20100113531 Thiazolidine derivatives as orexin receptor antagonists
05/06/2010US20100113529 Dosage regimen for comt inhibitors
05/06/2010US20100113521 Pharmaceutical compositions comprising 2-methoxy-5-(5-trifluoromethyl-tetrazol-1-yl-benzyl)-(2s-phenylpiperidin-3s-yl-)
05/06/2010US20100113515 Pten inhibitor or maxi-k channels opener
05/06/2010US20100113512 Method of treatment using novel antagonists or inverse agonists at opioid receptors
05/06/2010US20100113511 Mono Quaternary Ammonium Salts and Methods for Modulating Neuronal Nicotinic Acetylcholine Receptors
05/06/2010US20100113507 3-Tetrazolyl Indazoles, 3-Tetrazolyl Pyrazolopyridines, and use Thereof
05/06/2010US20100113502 Novel Tetrahydro-1H-Pyrido[4,3-b] Indole Derivatives as CB1 Receptor Ligands
05/06/2010US20100113500 Orally bioavailable products of (+)-3-hydroxymorphinan for parkinson's disease prevention or treatment
05/06/2010US20100113495 Pharmaceutical compositions comprising an opioid receptor antagonist and methods of using same
05/06/2010US20100113493 (pyrrolidin-2-yl)phenyl derivatives
05/06/2010US20100113486 Use of pde7 inhibitors for the treatment of movement disorders
05/06/2010US20100113485 Piperidinylamino-thieno[2,3-D] Pyrimidine Compounds
05/06/2010US20100113483 Compositions of 5-ht3 antagonists and dopamine d2 antagonists for treatment of dopamine-associated chronic conditions
05/06/2010US20100113482 Novel Compounds for Treating Mental Disorders, and Preparation and Uses Thereof
05/06/2010US20100113454 Pyrrolotriazine kinase inhibitors
05/06/2010US20100113453 Sublingual Formulations of D-Cycloserine and Methods of Using Same
05/06/2010US20100113451 Novel preventive and/or therapeutic agent for diabetic neuropathy
05/06/2010US20100113449 Fused heterocyclic compounds as ion channel modulators
05/06/2010US20100113446 Hydantoin compounds
05/06/2010US20100113435 Inhibitors of 11-beta-hydroxy steriod dehydrogenase type 1
05/06/2010US20100113432 Phenothiazine modulators of d2 receptors and 5-ht2 receptors
05/06/2010US20100113428 Diazabicyclic aryl derivatives as cholinergic receptor modulators
05/06/2010US20100113427 Compositions of 5-ht3 antagonists and dopamine d2 antagonists for treatment of dopamine-associated chronic conditions
05/06/2010US20100113424 N-benzyl pyrrolidine derivatives
05/06/2010US20100113422 Pyrimido [4,5-D] Azepine Derivatives As 5-HT2C Agonists
05/06/2010US20100113419 Cgrp receptor antagonists
05/06/2010US20100113417 Substituted Spiroamine Compounds
05/06/2010US20100113415 Epha4 rtk inhibitors for treatment of neurological and neurodegenerative disorders and cancer
05/06/2010US20100113411 Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions
05/06/2010US20100113396 Method and Composition for Potentiating an Opiate Analgesic
05/06/2010US20100113388 8-azaprostaglandin derivative compound and agent comprising the compound as active ingredient
05/06/2010US20100113379 cAMP DEPENDENT INDUCTION OF AUTOPHAGY
05/06/2010US20100113358 Leptin compositions and methods for treating progressive cognitive function disorders resulting from accumulation of neurofibrillary tangles and amlyoid beta
05/06/2010US20100113357 Platelet-derived growth factor-responsive neural precursor cells and progeny thereof
05/06/2010US20100113351 Therapeuting Compositions Comprising an RNAi Agent and a Neurotrophic Factor and Methods of Use Thereof
05/06/2010US20100113331 Substituted Imidazole Derivatives, Compositions, and Methods of Use as PtPase Inhibitors
05/06/2010US20100112634 Yeast strains autonomously producing steroids
05/06/2010US20100112107 Plant extract compositions for affecting sleep
1 ... 479 480 481 482 483 484 485 486 487 488 489 490 491 492 493 494 495 496 497 498 499 ... 1833